Inactive Instrument

Press Releases Biocept Inc Nasdaq

Equities

US09072V2043

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Biocept : Bankruptcy - Form 8-K	23-10-16	PU
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide Assay to Evaluate Patients with Leptomeningeal Metastases	23-09-22	AQ
Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept’s CNSide™ Assay to Evaluate Patients with Leptomeningeal Metastases	23-09-21	BU
Biocept Signs CNSide Licensing Agreement with plus Therapeutics	23-09-11	AQ
Biocept Signs CNSide™ Licensing Agreement with Plus Therapeutics	23-09-08	BU
Biocept to Participate in the H.C. Wainwright Global Investment Conference	23-09-05	BU
Biocept to Hold Business Update Conference Call on August 30, 2023	23-08-28	AQ
Biocept to Hold Business Update Conference Call on August 30, 2023	23-08-25	BU
Biocept's CNSide Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference	23-08-15	AQ
Biocept Reports Second Quarter 2023 Financial Results	23-08-14	BU
Biocept’s CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference	23-08-14	BU
Biocept Announces the Passing of Board Chair M. Faye Wilson	23-07-13	BU
Biocept Names Antonino Morales as President and Chief Executive Officer	23-06-20	BU
Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023	23-06-14	BU
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide Versus Cytology	23-06-06	AQ
Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept’s CNSide™ Versus Cytology	23-06-05	BU
Biocept Announces Pricing of $5.0 Million Underwritten Public Offering	23-05-24	BU
Biocept Announces One-for-Thirty Reverse Stock Split	23-05-17	BU
Biocept : Modification to Rights of Security Holders - Form 8-K	23-05-16	PU
BIOCEPT INC : Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)	23-05-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Biocept Inc Nasdaq

Equities

US09072V2043

Press Releases

Filters